<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01459484</url>
  </required_header>
  <id_info>
    <org_study_id>ISG/OS-2</org_study_id>
    <secondary_id>2011-001659-36</secondary_id>
    <nct_id>NCT01459484</nct_id>
  </id_info>
  <brief_title>ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma</brief_title>
  <acronym>ISG/OS-2</acronym>
  <official_title>ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma - Prospective Study (ISG/OS-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Italian Sarcoma Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Italian Sarcoma Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to assess the survival in patient with non metastatic
      osteosarcoma of the extremities treated with different chemotherapy protocols, according to
      the expression of ABCB1/P-glycoprotein
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Primary objective is:

      * Overall survival in patient with non metastatic osteosarcoma of the extremities treated
      with different chemotherapy approach (5 drugs vs 3 drugs), according to the expression of
      ABCB1/P-glycoprotein

      The Secondary objectives are:

        -  to assess the survival in patient who over express ABCB1/P-glycoprotein, with
           chemotherapy protocol based on all the 5 available active drugs (Methotrexate,
           cisplatinum, doxorubicine, ifosfamide and mifamurtide)

        -  to assess the survival in patient who do not over express ABCB1/P-glycoprotein
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>The patients will be followed in term of Overall Survival, for all the study period (expected average: 7 years)</time_frame>
    <description>The Overall Survival will be evaluated at the end of the study period (5 enrollment years and 2 years - minimum- follow-up from the last enrolled patient)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Events free survival in patient with ABCB1/P-glycoprotein over-expression, and who do not over-express ABCB1/P-glycoprotein</measure>
    <time_frame>after 2 and 3 years from the start of study</time_frame>
    <description>The events free survival will be evaluated by means of interim analysis after 2 and 3 years from the start of study. A further evaluation will be performed at the end of enrollment and after 2 years form the last enrolled patient.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Osteosarcoma</condition>
  <arm_group>
    <arm_group_label>Mifamurtide arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy for patients who over express ABCB1/P-glycoprotein (methotrexate, cisplatinum, doxorubicine, ifosfamide + mifamurtide)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 drugs arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>High grade osteosarcoma treatment for patients who do not over express ABCB1/P-glycoprotein</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifamurtide arm</intervention_name>
    <description>PRE SUGERY TREATMENT:
Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)
POST SURGERY TREATMENT for good responder patients with positive P-GLYCOPROTEIN
Methotrexate 12g/m2 (10 Cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total lenght treatment 44 weeks)
POST SURGERY TREATMENT for poor responder patients with positive P-GLYCOPROTEIN
Methotrexate 12g/m2; Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 ifosfamide 15g/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total lenght treatment 44 weeks)
All the product are used as commercial formulation</description>
    <arm_group_label>Mifamurtide arm</arm_group_label>
    <other_name>Methotrexate</other_name>
    <other_name>Cisplatinum</other_name>
    <other_name>doxorubicin</other_name>
    <other_name>ifosfamide</other_name>
    <other_name>mifamurtide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>3 drugs arm</intervention_name>
    <description>High grade osteosarcoma who do not over express ABCB1/P-glycoprotein will be treated with a standard 3-drugs regimen
PRE-SUGERY TREATMENT:
Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)
POST SURGERY TREATMENT:
Methotrexate 12g/m2 (10 cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2
Total lenght 34 weeks
All the product are used as commercial formulation</description>
    <arm_group_label>3 drugs arm</arm_group_label>
    <other_name>methotrexate</other_name>
    <other_name>cisplatin</other_name>
    <other_name>doxorubicine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histology confirmed diagnosis of extremities high grade osteosarcoma

          -  Age â‰¤ 40 years

          -  Localized disease or presence of skip metastasis

          -  Hepatic, renal and bone marrow normal function

          -  LVEF &gt; 50%

          -  No previous surgery and/ or chemotheraputic osteosarcoma treatments,

          -  No more than 4 weeks interval between histological diagnosis and start of chemotherapy

          -  Informed consent to the study participation obtained.

        Exclusion Criteria:

          -  Presence of metastases other than skip metastases

          -  Periosteal Osteosarcoma, parostal osteosarcoma, secondary osteosarcoma,

          -  Medical contra-indication to the drugs foreseen in the protocol,

          -  Subject is pregnant or breast feeding

          -  Mental or social conditions that can compromise a correct adherence to the protocol
             and its procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Ferrari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Italian Sarcoma Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefano Ferrari, MD</last_name>
    <phone>+390516366</phone>
    <phone_ext>411</phone_ext>
    <email>stefano.ferrari@ior.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emanuela Marchesi, PhD</last_name>
    <phone>+390516366</phone>
    <phone_ext>400</phone_ext>
    <email>emanuela.marchesi@ior.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>I.R.C.C. - Unit of Medical Oncology</name>
      <address>
        <city>Candiolo</city>
        <state>Torino</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanni Grignani, MD</last_name>
      <phone>+39.011.9933</phone>
      <phone_ext>278</phone_ext>
      <email>giovanni.grignani@ircc.it</email>
    </contact>
    <contact_backup>
      <last_name>Luisa Gioeni, Pharmacist</last_name>
      <phone>+39.011.9933</phone>
      <phone_ext>278</phone_ext>
      <email>luisa.gioeni@ircc.it</email>
    </contact_backup>
    <investigator>
      <last_name>Giovanni Grignani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Massimo Aglietta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Presidio Sanitario Gradenigo</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10153</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandro Comandone, MD</last_name>
      <phone>+390118151</phone>
      <phone_ext>211</phone_ext>
      <email>alessandro.comandone@gradenigo.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Comandone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Ortopedico Rizzoli</name>
      <address>
        <city>Bologna</city>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Ferrari, MD</last_name>
      <phone>+390516366</phone>
      <phone_ext>411</phone_ext>
      <email>stefano.ferrari@ior.it</email>
    </contact>
    <contact_backup>
      <last_name>Emanuela Marchesi, PhD</last_name>
      <phone>+390516366</phone>
      <phone_ext>400</phone_ext>
      <email>emanuela.marchesi@ior.it</email>
    </contact_backup>
    <investigator>
      <last_name>Stefano Ferrari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Meyer</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Tamburini, MD</last_name>
      <phone>+3905556</phone>
      <phone_ext>621</phone_ext>
      <email>a.tamburini@meyer.it</email>
    </contact>
    <investigator>
      <last_name>Angela Tamburini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carla Manzitti, MD</last_name>
    </contact>
    <investigator>
      <last_name>Carla Manzitti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FONDAZIONE IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rossella Bertulli, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rossella Bertulli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FONDAZIONE IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Luksch, MD</last_name>
    </contact>
    <investigator>
      <last_name>Roberto Luksch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori &quot;Fondazione G. Pascale&quot;</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gaetano Apice, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gaetano Apice, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianni Bisogno, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gianni Bisogno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituti Fisioterapici Ospitalieri di Roma</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginia Ferraresi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Virginia Ferraresi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambin Gesu'</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raffaele Cozza, MD</last_name>
    </contact>
    <investigator>
      <last_name>Raffaele Cozza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Infantile Regina Margherita - Unit of Paediatric Oncoematology</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franca Fagioli, MD</last_name>
      <phone>+39.011.3135</phone>
      <phone_ext>230</phone_ext>
      <email>franca.fagioli@unito.it</email>
    </contact>
    <investigator>
      <last_name>Franca Fagioli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Serra M, Pasello M, Manara MC, Scotlandi K, Ferrari S, Bertoni F, Mercuri M, Alvegard TA, Picci P, Bacci G, Smeland S. May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol. Int J Oncol. 2006 Dec;29(6):1459-68.</citation>
    <PMID>17088985</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2011</study_first_submitted>
  <study_first_submitted_qc>October 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2011</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non metastatic extremities high grade osteosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Krestin</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Mifamurtide</mesh_term>
    <mesh_term>Acetylmuramyl-Alanyl-Isoglutamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

